FDA’s New CDER Director Allows Approval Of Yet Another Expensive, Scientifically Worthless Drug. Expect Many More.

EXCERPT: The FDA’s Center for Drug Evaluation and Research (CDER) approval of aducanumab (Aduhelm) for Alzheimer’s is the latest in a series of decisions where the FDA appeared to bow to politics and public pressure rather than scientific findings.